A comparison of tau and 14-3-3 protein in the diagnosis of Creutzfeldt-Jakob disease

Neurology

Volumn 79, Issue 6, 2012, Pages 547-552

  Hamlin, Clive ^a   Puoti, Gianfranco ^a   Berri, Sally ^a   Sting, Elliott ^a   Harris, Carrie ^a   Cohen, Mark ^a   Spear, Charles ^a   Bizzi, Alberto ^c   Debanne, Sara M ^b   Rowland, Douglas Y ^b  

^a Department of Pathology ^*  (Italy)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN 14 3 3; TAU PROTEIN;

ARTICLE; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; WESTERN BLOTTING;

EID: 84866140422     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318263565f     Document Type: Article

References (26)

1. Schapira AH, Tolosa E. Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat Rev Neurol 2010;6:309 -317
2. Hampel H, Frank R, Broich K, et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 2010;9:560 -574
3. Hsich G, Kenney K, Gibbs CJ, Lee KH, Harrington MG. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med 1996;335:924 -930
4. Sanchez-Juan P, Sánchez-Valle R, Green A, et al. Influence of timing on CSF tests value for Creutzfeldt-Jakob disease diagnosis. J Neurol 2007;254:901-906
5. Collins J, Sanchez-Juan P, Masters CL, et al. Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease. Brain 2006;129:2278 -2287
6. Gambetti P, Kong Q, Zou W, Parchi P, Chen SG. Sporadic and familial CJD: classification and characterisation. Br Med Bull 2003;66:213-239
7. Gmitterova K, Heinemann U, Bodemer M, et al. 14-3-3 CSF levels in sporadic Creutzfeldt-Jakob disease differ across molecular subtypes. Neurobiol Aging 2009;30: 1842-1850
8. Van Everbroeck B, Quoilins, Boon J, Martin JJ, Cras P. A prospective study of CSF markers in 250 patients with possible Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 2003;74:1210 -1214
9. Chapman T, McKeel DW Jr, Morris JC. Misleading results with the 14-3-3 assay for the diagnosis of Creutzfeldt- Jakob disease. Neurology 2000;55:1396 -1397
10. Geschwind M, Martindale J, Miller D, et al. Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt-Jakob disease. Arch Neurol 2003;60: 813-816
11. Kenney K, Brechtel C, Takahashi H, Kuroharak K, Anderson P, Gibbs CJ Jr. An enzyme-linked immunosorbent assay to quantify 14-3-3 proteins in the cerebrospinal fluid of suspected Creutzfeldt-Jakob disease patients. Ann Neurol 2000;48:395-398
12. Otto M, Wiltfang J, Cepek L, et al. Tau protein and 14- 3-3 protein in the differential diagnosis of Creutzfeldt- Jakob disease. Neurology 2002;58:192-197
13. Bahl JM, Heegaard NH, Falkenhorst G, et al. The diagnostic efficiency of biomarkers in sporadic Creutzfeldt- Jakob disease compared to Alzheimer's disease. Neurobiol Aging 2009;30:1834 -1841
14. Beaudry P, Cohen P, Brandel JP, et al. 14-3-3 protein, neuron-specific enolase, and S-100 protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord 1999;10:40-46
15. Kropp S, Zerr I, Schulz-Schaeffer WJ, et al. Increase of neuron-specific enolase in patients with Creutzfeldt-Jakob disease. Neurosci Lett 1999;261:124 -126
16. Kohira I, Tsuji T, Ishizu H, et al. Elevation of neuronspecific enolase in serum and cerebrospinal fluid of early stage Creutzfeldt-Jakob disease. Acta Neurol Scand 2000; 102:385-387
17. Otto M, Wiltfang J, Tumani H, et al. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci Lett 1997;225:210- 212
18. Parchi P, Giese A, Capellari S, et al. Classification of sporadic Creutzfeldt-Jakob Disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 1999;46: 224-233
19. Monari L, Chen SG, Brown P. Fatal familial insomnia and familial Creutzfeldt-Jakob disease: different prion proteins determined by a DNA polymorphism. Natl Acad Sci 1994;91:2839 -2842
20. Ironside JW, Head MW. Neuropathology and molecular biology of variant Creutzfeldt-Jakob disease. Curr Top Microbiol Immunol 2004;284:133-159
21. Chitravas N, Jung RS, Kofskey DM, et al. Treatable neurological disorders misdiagnosed as Creutzfeldt-Jakob disease. Ann Neurol 2011;70:437-444
22. Sanchez-Juan P, Green A, Ladogana A, et al. CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 2006;67637-67643
23. Van Everbroeck B, Boons J, Cras P. Cerebrospinal fluid biomarkers in Creutzfeldt-Jakob disease. Clin Neurol Neurosurg 2005;107:355-360
24. Skinningsrud A, Stenset V, Gundersen AS, Fladby T. Cerebrospinal fluid markers in Creutzfeldt-Jakob disease. Cerebrospinal Fluid Res 2008;5:14
25. Wang GR, Gao C, Shi Q, et al. Elevated levels of tau protein in cerebrospinal fluid of patients with probable in Creutzfeldt-Jakob disease. Am J Med Sci 2010;340:291- 295
26. Boesenberg-Grosse C, Shulz-Schaeffer WJ, Bodemer M, et al. Brain-derived proteins in CSF: do they correlate with brain pathology in CJD? BMC Neurol 2006;6:35.